<DOC>
	<DOCNO>NCT00210379</DOCNO>
	<brief_summary>The primary objective ass clinical activity combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 ( Rituximab ) plus intrathecal prophylactic chemotherapy loco-regional radiotherapy primary localise testicular DLCL ass toxicity therapeutic strategy</brief_summary>
	<brief_title>Phase II Study Combined Modality Treatment Primary Testicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1. age = 18 year . 2 . ECOG performance status 02 3 . Histologically proven primary testicular CD20positive diffuse large Bcell nonHodgkin 's lymphoma , untreated 4 . Ann Arbor stage IE IIE . Bilateral testicular involvement presentation consider stage IV . In patient final Ann Arbor stage determine extent nodal involvement . 5 . Bidimensionally measurable evaluable disease . Patients disease remove surgery eligible . 6 . Adequate bone marrow reserve ( ANC &gt; 1.000/L , Plt &gt; 100.000/L ) 7 . Cardiac ejection fraction â‰¥ 50 % MUGA scan echocardiography 8 . No previous therapy monoclonal antibody antiCD20 . 9 . No psychiatric illness precludes understanding concept trial signing inform consent 10 . No major lifethreatening illness may preclude chemotherapy 11 . Have give write informed consent prior programspecific screen procedure , understanding consent may withdraw patient time without prejudice 1. impairment renal function ( creatinine &gt; 2 mg/dl ) liver function ( bilirubin &gt; 2 mg/dl ) unless due lymphoma involvement 2 . HIV positive patient 3. evolutive malignancy within 5 year exception localize nonmelanomatous skin cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>